| Autor: |
G. Ravi Kiran, P. Chandrasekhar, S. Mohammad Ali |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Indian Heart Journal, Vol 73, Iss 3, Pp 365-368 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
0019-4832 |
| DOI: |
10.1016/j.ihj.2021.02.005 |
| Popis: |
Agent of choice for thrombolytic therapy (TT) in prosthetic valve thrombosis (PVT) is unknown. 84 mitral obstructive-PVT episodes treated with TT (43: Tenecteplase; 41: Streptokinase) were included in this prospective study. The incidence of primary end-point (CCS: complete clinical success, defined as complete or partial hemodynamic success with no complications or surgery) was 84.5% with recurrent PVT as a sole predictor. Bleeding and embolic manifestations were noted in 8.3% and 4.7% of episodes respectively. Tenecteplase use was associated with lower complication rate and a mitral EOA of |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
